» Articles » PMID: 20102756

Postoperative Use of Bisphosphonates and Risk of Revision After Primary Total Hip Arthroplasty: a Nationwide Population-based Study

Overview
Journal Bone
Date 2010 Jan 28
PMID 20102756
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recently, bisphosphonates have been linked with mechanisms that may influence longevity of orthopedic implants. We therefore evaluated the association between the use of bisphosphonates and the risk of revision after primary total hip arthroplasty (THA).

Methods: We conducted a nationwide population-based nested case-control study using medical databases in Denmark. From the Danish Hip Arthroplasty Register (DHR) we included primary THA patients diagnosed with either osteoporosis or a previous osteoporotic fracture (n=16,145). Among these patients we identified 632 cases that were revised after primary THA in the period 1995-2006. The cases were matched on gender, age and year of primary THA surgery with 1262 non-revised osteoporotic THA controls. Using conditional logistic regression we estimated the risk of revision due to all causes and due to specific causes according to postoperative bisphosphonate use.

Results: The 10-year cumulated implant revision rate in the underlying cohort of 16,145 primary THA procedures among osteoporotic patients was 8.3% (95% confidence interval (CI): 7.3-9.3). The use of bisphosphonates was associated with an adjusted relative risk of revision due to deep infections of 2.59 (95% CI; 1.30-6.53). Further, the duration of bisphosphonates use up to 120days, 120 and 240days, and more than 240days was associated with adjusted relative risks of revision due to all causes of 2.77 (95% CI; 1.65-4.64), 1.33 (95% CI; 0.63-2.72), and 0.58 (95% CI; 0.32-1.05) respectively.

Conclusions: The use of bisphosphonates following primary THA was associated with an increased risk of revision due to deep infection. However, long-term use was associated with a reduced risk of revision of any type. Further research is warranted in order to clarify whether these associations are truly causal.

Citing Articles

Evidence-based joint statement position of perioperative bone optimization in the arthroplasty candidate, from FEMECOT, AMMOM, ACOMM, SCCOT, SECOT, SEFRAOS, SEIOMM.

Enrique L, Francisco T, Inigo E, Cristina O, Francisco L, Angel G Osteoporos Int. 2025; 36(3):375-389.

PMID: 39934392 DOI: 10.1007/s00198-025-07411-6.


Does Preoperative Bisphosphonate Use Impact the Risk of Periprosthetic Fracture Following Total Hip Arthroplasty?.

Busigo Torres R, Hong J, Kodali H, Poeran J, Stern B, Hayden B J Arthroplasty. 2024; 40(3):700-704.e1.

PMID: 39233096 PMC: 11810596. DOI: 10.1016/j.arth.2024.08.043.


Postoperative Bisphosphonates Use is Associated with Reduced Adverse Outcomes After Primary Total Joint Arthroplasty of Hip and Knee: A Nationwide Population-Based Cohort Study.

Shih J, Tan T, Shen P, Yeh T, Wu C, Pan R Calcif Tissue Int. 2024; 114(5):451-460.

PMID: 38492035 DOI: 10.1007/s00223-024-01192-6.


Bisphosphonates' use and risk of aseptic loosening following total hip arthroplasty: a systematic review.

Pegios V, Kenanidis E, Tsotsolis S, Potoupnis M, Tsiridis E EFORT Open Rev. 2023; 8(11):798-808.

PMID: 37909705 PMC: 10646521. DOI: 10.1530/EOR-22-0121.


Additive Effect of Parathyroid Hormone and Zoledronate Acid on Prevention Particle Wears-Induced Implant Loosening by Promoting Periprosthetic Bone Architecture and Strength in an Ovariectomized Rat Model.

Zhou C, Wang Y, Meng J, Yao M, Xu H, Wang C Front Endocrinol (Lausanne). 2022; 13:871380.

PMID: 35546997 PMC: 9084285. DOI: 10.3389/fendo.2022.871380.